Overview

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

Status:
RECRUITING
Trial end date:
2026-06-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
Phase:
PHASE2
Details
Lead Sponsor:
Janssen Research & Development, LLC